Vincristine sulfate

製品コードS1241 バッチS124108

化学情報

	Synonyms	Leurocristine sulfate, NSC-67574 sulfate, 22-Oxovincaleukoblastine sulfate	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₄₆H₅₈N₄O₁₄S
	分子量	923.04	CAS No.	2068-78-2
Solubility (25°C)*	体外	DMSO	100 mg/mL (108.33 mM)
		Water	100 mg/mL (108.33 mM)
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
in vitro	Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with K_i of 85 nM. ^[1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. ^[2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. ^[4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. ^[5]
in vivo	Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. ^[6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . ^[7]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	B16 melanoma cell
	濃度	10 nM
	反応時間	3 days
	実験の流れ	Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
動物実験	動物モデル	Human rhabdomyosarcoma xenografts Rh12
	投薬量	3 mg/kg
	投与方法	A single i.p. administration

参考

+ 展开

カスタマーフィードバック

: Data from [Int J Mol Sci, 2012, 13, 10736-10749 ]

: Data from [Data independently produced by , , Cancer Research, 2013, 73(20): 6310-22 ]

: Data from [Data independently produced by , , Cell Death & Disease, 2017, doi:10.1038/cddis.2017.454]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

EFNB1 levels determine distinct drug response patterns guiding precision therapy for B-cell neoplasms [ iScience, 2024, 27(1):108667]	PubMed: 38155773
Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers [ Cell Rep Med, 2023, 4(12):101339]	PubMed: 38118405
Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging [ Acta Neuropathol Commun, 2023, 11(1):6]	PubMed: 36631900
Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma [ Int J Mol Sci, 2023, 10.3390/ijms242115571]	PubMed: 37958555
Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature [ Cancers (Basel), 2023, 15(4)1086]	PubMed: 36831428
In ovo chorioallantoic membrane assay as a xenograft model for pediatric rhabdomyosarcoma [ Oncol Rep, 2023, 49(4)76]	PubMed: 36866753
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization [ Cell Rep Methods, 2023, 3(10):100599]	PubMed: 37797618
Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis [ Nat Cell Biol, 2022, 10.1038/s41556-021-00814-7]	PubMed: 35145224
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies [ Blood, 2022, blood.2021014304]	PubMed: 35704690
Functional, structural and molecular characterizations of leukemogenic driver MEF2D-HNRNPUL1 fusion [ Blood, 2022, blood.2022016241]	PubMed: 35544603

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。